Cresco Labs (CRLBF) to Release Earnings on Thursday

Cresco Labs (OTCMKTS:CRLBF) is projected to issue its results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $160.8740 million for the quarter.

Cresco Labs Stock Up 2.5%

CRLBF stock opened at $0.94 on Wednesday. The company has a 50 day moving average of $1.13 and a two-hundred day moving average of $1.14. The company has a market cap of $334.37 million, a price-to-earnings ratio of -6.23 and a beta of 1.47. Cresco Labs has a 12-month low of $0.43 and a 12-month high of $2.30. The company has a quick ratio of 1.54, a current ratio of 2.49 and a debt-to-equity ratio of 1.28.

Analyst Upgrades and Downgrades

CRLBF has been the subject of several recent research reports. ATB Cormark Capital Markets upgraded Cresco Labs to an “outperform” rating in a report on Tuesday, December 2nd. Zacks Research lowered Cresco Labs from a “hold” rating to a “strong sell” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Cresco Labs has a consensus rating of “Moderate Buy”.

Cresco Labs Company Profile

Cresco Labs is a vertically integrated, multi-state cannabis operator in the United States. The company engages in the cultivation, manufacturing and distribution of a broad range of cannabis products, including flower, pre-rolled joints, concentrates, vaporizers, edibles and tinctures. Cresco Labs’ operations span cultivation facilities, processing laboratories and a network of wholesale distribution centers that supply licensed dispensaries and retail outlets across key cannabis markets.

The company’s product portfolio is organized under several branded platforms, such as MÜV, Reserve and High Supply, each designed to address different segments of the adult-use and medical cannabis markets.